{"id":"NCT01626859","sponsor":"Mitsubishi Tanabe Pharma Corporation","briefTitle":"A Pharmacokinetic Study of MP-214 in Patients With Schizophrenia","officialTitle":"A Pharmacokinetic Study of MP-214 in Patients With Schizophrenia (12 Weeks Treatment Study)","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2012-05","primaryCompletion":"2013-08","completion":"2013-08","firstPosted":"2012-06-25","resultsPosted":"2021-04-12","lastUpdate":"2021-04-12"},"enrollment":38,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Schizophrenia"],"interventions":[{"type":"DRUG","name":"MP-214 3mg","otherNames":[]},{"type":"DRUG","name":"MP-214 6mg","otherNames":[]},{"type":"DRUG","name":"MP-214 9mg","otherNames":[]}],"arms":[{"label":"MP-214 3mg","type":"EXPERIMENTAL"},{"label":"MP-214 6mg","type":"EXPERIMENTAL"},{"label":"MP-214 9mg","type":"EXPERIMENTAL"}],"summary":"The objective of this study is to evaluate the pharmacokinetics, safety and efficacy of MP-214 in patients with schizophrenia.","primaryOutcome":{"measure":"Number of Participants With Adverse Events as a Measure of Safety and Tolerability","timeFrame":"Up to 24 weeks","effectByArm":[{"arm":"MP-214 3mg","deltaMin":11,"sd":null},{"arm":"MP-214 6mg","deltaMin":15,"sd":null},{"arm":"MP-214 9mg","deltaMin":11,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":1},"locations":{"siteCount":1,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":11},"commonTop":["Restlessness","Akathisia","Nasopharyngitis","Insomnia","Schizophrenia"]}}